Seneca Therapeutics, Inc (STI)
Seneca Therapeutics product - SVV-001 - is an extremely versatile virus able to make resistant tumors susceptible again and to deliver genes into TEM8 tumors
- Stage Full Product Ready
- Industry Biotechnology
- Location Philadelphia, PA, USA
- Currency USD
- Founded February 2018
- Employees 4
- Incorporation Type C-corp
- Website senecatherapeutics.com
STI is developing SVV-001 for cancer treatment. SVV-001 can be used in combination with checkpoint inhibitors (Opdivo). SVV-001 can also be used as a viral vector to deliver genes and other drugs to TEM8 positive solid tumors. STI has also developed a SVV-001 Patient Selection Test to proactively identify patients with SVV-001 sensitive tumors. STI is also developing SVV-001 using intravenous and intratumoral dosing protocols.
Dr. Hallenbeck is the Founder, President and CSO of Seneca. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immuno-therapeutics R&D. As the sole founder of Neotropix, raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed a Phase I/II clinical trial, establishing an excellent safety record & compelling evidence of efficacy.
Dr. Wechuck is a biochemical engineer with 15 yrs of experience in recombinant protein production, viral vector manufacturing, and biologics testing. He has developed and advanced the proprietary cGMP manufacturing production, purification, and formulation methodologies for Type 1 Diabetes Drug Products and viral vectors for gene therapy products. He has led CMC regulatory elements for several investigational drug applications in the US & Europe.
Dr. Sankar is President & Founder of SwanBio, LLC, a BD & Clinical Strategy consultancy firm that facilitates the translation of scientific discoveries into cancer therapeutics. An expert in global clinical development and regulatory strategies for therapeutic drugs; he has led numerous clinical trials in oncology therapy ranging from breast, ovarian, pancreatic, liver, lung, and connective tissue tumors, to a range of hematological malignancies.
Dr, Chada's drug development expertise includes antibodies, cell and gene therapies and small molecules for oncology, genetic diseases and immunotherapy. He is an expert in translating product concepts into clinical trials: >15 INDs; >20 Phase I-III. Dr. Chada is an adjunct faculty member in Dept. Experimental Therapeutics at MD Anderson Cancer Center. He is also a special advisor to the chief scientific officer of MDACC Moonshots Initiative.
Jim Hussey is a pharmacist with an MBA who has spent the last 20 years in pharma & biotech C-suite positions. Most recently he was interim President at Morphosys. Jim has raised over $600M throughout his career. and has a proven track record of successful IPO's, acquisitions, as well as profitable liquidity exits. Jim is a KOL in the I/O space and has a very keen strategic sense to align Seneca Therapeutics with a successful BD partnership.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.